Dataset Information
Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting.
Ontology highlight
ABSTRACT: Background
Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules on the surface of malignant plasma cells and CD3 on the surface of T cells.Objectives
Addressing the issue of improving the prognosis of triple-class refractory MM patients has become a significant clinical challenge.Design
This is a brief report.Methods
This article summarizes the latest updates of BsAbs treatment of MM from the 2022 ASH annual meeting.Results
BsAbs that target B-cell maturation antigen and G protein-coupled receptor family C group 5 memberD have demonstrated remarkable clinical activity and favorable safety profiles. Many potential targets for myeloma cells are currently undergoing phase I/II clinical trials, and these off-the-shelf bispecific molecules are likely to become a critical part of the MM treatment landscape.Conclusion
This article provides an overview of the latest advances in BsAbs immunotherapy for refractory and relapsed MM and highlights significant findings from the 2022 ASH annual meeting.
SUBMITTER: Yin X
PROVIDER: S-EPMC10657518 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
Publications
Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting.
Therapeutic advances in chronic disease 20231118
<h4>Background</h4>Effective novel therapies for multiple myeloma (MM) patients who are unresponsive to conventional treatments (triple-class refractory) are an urgent need. Bispecific antibodies (BsAbs) offer a promising new approach to stimulate T cells and induce tumor cell death by targeting molecules on the surface of malignant plasma cells and CD3 on the surface of T cells.<h4>Objectives</h4>Addressing the issue of improving the prognosis of triple-class refractory MM patients has become a ...[more]